T cell responses against tumor associated antigens and prognosis in colorectal cancer patients

被引:20
作者
Nagorsen, D
Scheibenbogen, C
Letsch, A
Germer, CT
Buhr, HJ
Hegewisch-Becker, S
Rivoltini, L
Thiel, E
Keilholz, U
机构
[1] Charite Univ Med Berlin, Dept Surg, Berlin, Germany
[2] Univ Clin Eppendorf, Dept Hematol & Oncol, Hamburg, Germany
[3] Ist Nazl Tumori, I-20133 Milan, Italy
关键词
D O I
10.1186/1479-5876-3-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction: Spontaneous T cell responses against specific tumor-associated antigens ( TAA) are frequently detected in peripheral blood of tumor patients of various histiotypes. However, little is known about whether these circulating, spontaneously occurring, TAA-reactive T cells influence the clinical course of disease. Methods: Fifty-four HLA-A2 positive colorectal cancer patients had been analyzed for the presence of T cell responses against epitopes derived from the TAA Ep-CAM, her-2/neu, and CEA either by ELISPOT assay or by intracellular cytokine staining. Then, Kaplan-Meier survival analysis was performed comparing T-cell-responders and T-cell-non-responders. For comparison, a group of T-cell-non-responders was compiled stringently matched to T-cell-responders based on clinical criteria and also analyzed for survival. Results: Sixteen out of 54 patients had a detectable T cell response against at least one of the three tested TAA. Two out of 21 patients (9.5%) with limited stage of disease (UICC I and II) and 14 out of 33 patients (42.4%) with advanced disease (UICC III and IV) were T cell response positive. Comparing all T-cell-responders (n = 16) and all T-cell-non-responders (n = 38), no survival difference was found. In an attempt to reduce the influence of confounding clinical factors, we then compared 16 responders and 16 non-responders in a matched group survival analysis; and again no survival difference was found (p = 0.7). Conclusion: In summary, we found no evidence that spontaneous peripheral T cell responses against HLA-A2-binding epitopes of CEA, her-2/neu and Ep-CAM are a strong prognostic factor for survival.
引用
收藏
页数:6
相关论文
共 46 条
[21]  
Mortarini R, 2003, CANCER RES, V63, P2535
[22]  
Nagorsen D, 2000, CANCER RES, V60, P4850
[23]  
Nagorsen D, 2003, CLIN CANCER RES, V9, P4296
[24]   Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients [J].
Nagorsen, D ;
Scheibenbogen, C ;
Schaller, G ;
Leigh, B ;
Schmittel, A ;
Letsch, A ;
Thiel, E ;
Keilholz, U .
INTERNATIONAL JOURNAL OF CANCER, 2003, 105 (02) :221-225
[25]  
Naito Y, 1998, CANCER RES, V58, P3491
[26]  
Öberg Å, 2002, INT J COLORECTAL DIS, V17, P25
[27]  
Parmiani Giorgio, 2002, Cancer Immun, V2, P6
[28]   The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes [J].
Peiper, M ;
Goedegebuure, PS ;
Linehan, DC ;
Ganguly, E ;
Douville, CC ;
Eberlein, TJ .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (05) :1115-1123
[29]   Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression [J].
Pellegrini, P ;
Berghella, AM ;
DelBeato, T ;
Cicia, S ;
Adorno, D ;
Casciani, CU .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 42 (01) :1-8
[30]   BREAST AND OVARIAN CANCER-SPECIFIC CYTOTOXIC T-LYMPHOCYTES RECOGNIZE THE SAME HER2/NEU-DERIVED PEPTIDE [J].
PEOPLES, GE ;
GOEDEGEBUURE, PS ;
SMITH, R ;
LINEHAN, DC ;
YOSHINO, I ;
EBERLEIN, TJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (02) :432-436